Skip to content
Open access

Peripheral GALR2 activation by the metabolically stabilized spexin analog LIT-01-144 produces potent opioid‑independent antinociception.

Oct 2026 · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · Vol 204, pp. 119987 · 0 citations · 51 references
Medicine

TL;DR

LIT-01-144 is designed and characterized, a modified spexin analog incorporating N-terminal fluorocarbon functionalization to improve metabolic stability while preserving receptor selectivity, and demonstrated the potential of LIT-01-144 as a valuable tool for understanding GALR2-mediated mechanisms of pain modulation.

Abstract

Chronic pain constitutes a major global health burden, and current management remains largely dependent on opioid analgesics, which are associated with opioid use disorder. Accordingly, there is a pressing need to identify non-opioid therapeutic strategies. Galanin receptors (GALR1-3) have been implicated in pain modulation, but their individual roles remain insufficiently defined because of the absence of subtype-selective ligands. Recently, spexin has been identified as an endogenous peptide that selectively activates GALR2 and GALR3, offering a new scaffold for developing pharmacological tools targeting these receptor subtypes. In this study, we designed and characterized LIT-01-144, a modified spexin analog incorporating N-terminal fluorocarbon functionalization to improve metabolic stability while preserving receptor selectivity. In vitro pharmacological profiling demonstrated high potency at GALR2 and GALR3, with negligible activity at GALR1. Pharmacokinetic analyses showed a substantially prolonged plasma half-life relative to native spexin and no evidence of central nervous system penetration. In vivo, intracerebroventricular administration of LIT-01-144 produced robust antinociception at doses tenfold lower than those required for spexin. Although systemic administration had no detectable effect in naïve mice, it significantly attenuated pain-related behaviors in a model of persistent inflammatory pain. This effect was mediated specifically by GALR2 and was independent of opioid receptor signaling. In situ hybridization further showed an increase in Galr2 + neurons in dorsal root ganglia of inflamed mice. Collectively, these findings highlight GALR2 as a promising peripheral target for developing non-opioid analgesics and demonstrate the potential of LIT-01-144 as a valuable tool for understanding GALR2-mediated mechanisms of pain modulation.

Read PDF

Similar papers

Open access Nov 2026

Design, Synthesis, and Pharmacological Characterization of Novel Kappa Opioid Receptor Agonists via Isosteric Replacement Strategy for Inflammatory Pain

Pharmacokinetic studies identified compound 10 as a P-glycoprotein substrate with limited brain exposure, consistent with a CNS-sparing profile and preferentially peripheral activity, and was identified as a KOR-mediated antinociception candidate.

Ahmed M. Reda, Logan T. Neel, Celsey M. St. Onge et al. · 0 citations
Sep 2026

Two-Step Design of Triazole-Stapled Opioid Agonists Exhibiting Potent and Prolonged Peripheral Analgesic Activity.

This study establishes a two-step strategy for developing triazole-stapled multifunctional agonists that integrate opioid and neuropeptide FF (NPFF) pharmacophores. Initially, calcium mobilization assays, enzymatic stability tests, and analgesic activity screens identified triazole-stapled opioid peptide 16, derived fr...

Meng-Na Zhang, Jie Gao, Jia-Min Feng et al. · 0 citations
Open access Oct 2026

Chemical Determinants of Spinal Analgesia in NTS2-Selective Macrocycles.

Neurotensin (NT)-based ligands represent promising non-opioid analgesics. Here, we designed and synthesized a focused library of macrocyclic NT analogs combining substitutions previously shown to enhance NTS2 affinity, selectivity, and/or antinociceptive activity. Several macrocycles retained low-nanomolar NTS2 affinit...

Michael Desgagné, Nathan Meneboo, Magali Chartier et al. · 0 citations
Open access Sep 2026

Impact of Cannabidiol and Its Synthetic Derivative on Fentanyl Consumption and Fentanyl-Induced Neurometabolic Alterations in Mice

These studies provide evidence about the in vivo behavioral and neurometabolic profiles of fentanyl after pretreatment with CBD and synthetic CBD, presenting them as possible pharmacological tools for OUD research.

Dalal A. Alkhelb, Jomana M. Alahmadi, Maisa S. Alqarni et al. · 0 citations
Open access Oct 2026

Discovery of a Peripherally Directed CB1 Receptor Antagonist That Restores Insulin Signaling in Adipocytes

Piperazine-1-ium derivative 24a stands out as the first permanently charged CB1R antagonist, exhibiting nanomolar affinity and high CB1R/CB2R selectivity with a favorable physicochemical profile consistent with peripheral restriction and limited blood-brain barrier penetration.

J. Azuaje, Rubén Prieto-Díaz, Claudia Gioé-Gallo et al. · 0 citations
Open access Oct 2026

CVN636 potentiates orthosteric agonist responses selectively at mGlu 7/7 homodimers

The metabotropic glutamate receptor 7 (mGlu7) is an emerging therapeutic target for central nervous system disorders, but progress has been limited by a lack of selective pharmacological tools. CVN636 was recently reported as a potent and selective allosteric agonist of this receptor, capable of receptor activation in...

Xin Lin, C. Niswender, Wesley B. Asher et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.